Johnson & Johnson is a diversified healthcare leader spanning pharmaceuticals and medical devices. Following the Kenvue (consumer health) spin-off in 2023, J&J is now focused on Innovative Medicine and MedTech.
Immunology, Oncology, Neuroscience, Medical Devices
5-year financial trajectory
Business segment breakdown
Key product revenue comparison
Geographic revenue split
| Product | Indication | Revenue |
|---|---|---|
| Stelara (ustekinumab) | Immunology | $9.8B |
| Darzalex (daratumumab) | Oncology (MM) | $9.0B |
| Tremfya (guselkumab) | Immunology | $3.0B |
| Xarelto (rivaroxaban) | Cardiology | $7.0B |
| Erleada (apalutamide) | Oncology (prostate) | $4.5B |
| Tecvayli (teclistamab) | Oncology (MM) | $0.4B |
J&J is the #2 pharma company globally. Post-Kenvue spin-off, focus is purely on pharma and medtech. Stelara biosimilar cliff (2025) is key risk, offset by Darzalex, Tremfya, and bispecific pipeline.
Revenue projected at $85-90B through 2026. Stelara biosimilar erosion offset by Tremfya expansion and Darzalex growth. Bispecific antibody platform (Tecvayli, Talvey) represents next growth wave.
Johnson & Johnson 2023 Annual Report (Form 10-K). Revenue and financial data from SEC filings (Form 10-K/20-F). Pipeline data from company R&D presentations and ClinicalTrials.gov. Market analysis by Medifirm Intelledge Global.